Goodwin Procter LLP advised AbSci on the deal.AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, announced a $125 million crossover financing. The round…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
